CN117042770A - 用于患有高脂血症或混合性血脂异常的他汀类不耐受患者的奥比塞曲匹与依折麦布的组合治疗 - Google Patents
用于患有高脂血症或混合性血脂异常的他汀类不耐受患者的奥比塞曲匹与依折麦布的组合治疗 Download PDFInfo
- Publication number
- CN117042770A CN117042770A CN202280015230.8A CN202280015230A CN117042770A CN 117042770 A CN117042770 A CN 117042770A CN 202280015230 A CN202280015230 A CN 202280015230A CN 117042770 A CN117042770 A CN 117042770A
- Authority
- CN
- China
- Prior art keywords
- ezetimibe
- combination
- ldl
- day
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2021050109 | 2021-02-18 | ||
| NLPCT/NL2021/050109 | 2021-02-18 | ||
| PCT/NL2022/050083 WO2022177428A1 (en) | 2021-02-18 | 2022-02-18 | Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117042770A true CN117042770A (zh) | 2023-11-10 |
Family
ID=74844966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280015230.8A Pending CN117042770A (zh) | 2021-02-18 | 2022-02-18 | 用于患有高脂血症或混合性血脂异常的他汀类不耐受患者的奥比塞曲匹与依折麦布的组合治疗 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240189311A1 (https=) |
| EP (1) | EP4294387A1 (https=) |
| JP (1) | JP2024507810A (https=) |
| KR (1) | KR20230159380A (https=) |
| CN (1) | CN117042770A (https=) |
| AU (1) | AU2022223224A1 (https=) |
| BR (1) | BR112023016682A2 (https=) |
| CA (1) | CA3210033A1 (https=) |
| IL (1) | IL304544A (https=) |
| MX (1) | MX2023009613A (https=) |
| WO (1) | WO2022177428A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12006305B2 (en) | 2022-07-05 | 2024-06-11 | Newamsterdam Pharma B.V. | Salts of obicetrapib and processes for their manufacture and intermediates thereof |
| WO2024165395A1 (en) * | 2023-02-07 | 2024-08-15 | Newamsterdam Pharma B.V. | Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions |
| WO2025146445A1 (en) * | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Pharmaceutical compositions of obicetrapib and ezetimibe |
| WO2025146262A1 (en) * | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Obicetrapib for use in the treatment of hemoglobinopathies |
| WO2025146446A1 (en) * | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Pharmaceutical compositions of obicetrapib |
| WO2025147235A1 (en) * | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Fixed dose combination composition of obicetrapib and ezetimibe |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| MX369471B (es) * | 2014-02-05 | 2019-11-08 | Dezima Pharma B V | Inhibidor de proteina de transferencia del ester de colesterilo (cetp) y composiciones farmaceuticas que comprenden el inhibidor para uso en el tratamiento o prevencion de enfermedades cardiovasculares. |
| WO2017023166A1 (en) * | 2015-08-04 | 2017-02-09 | Dezima Pharma B.V. | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and a cholesterol absorption inhibitor |
| US12006305B2 (en) * | 2022-07-05 | 2024-06-11 | Newamsterdam Pharma B.V. | Salts of obicetrapib and processes for their manufacture and intermediates thereof |
| JP2025527686A (ja) * | 2022-08-22 | 2025-08-22 | ニューアムステルダム・ファルマ・ベー・フェー | オビセトラピブ及びエゼチミブ併用治療及び固定用量医薬組成物 |
-
2022
- 2022-02-18 CN CN202280015230.8A patent/CN117042770A/zh active Pending
- 2022-02-18 JP JP2023549866A patent/JP2024507810A/ja active Pending
- 2022-02-18 AU AU2022223224A patent/AU2022223224A1/en active Pending
- 2022-02-18 KR KR1020237028087A patent/KR20230159380A/ko active Pending
- 2022-02-18 CA CA3210033A patent/CA3210033A1/en active Pending
- 2022-02-18 MX MX2023009613A patent/MX2023009613A/es unknown
- 2022-02-18 BR BR112023016682A patent/BR112023016682A2/pt unknown
- 2022-02-18 EP EP22705485.5A patent/EP4294387A1/en active Pending
- 2022-02-18 US US18/277,851 patent/US20240189311A1/en active Pending
- 2022-02-18 WO PCT/NL2022/050083 patent/WO2022177428A1/en not_active Ceased
-
2023
- 2023-07-18 IL IL304544A patent/IL304544A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024507810A (ja) | 2024-02-21 |
| AU2022223224A1 (en) | 2023-08-24 |
| IL304544A (en) | 2023-09-01 |
| MX2023009613A (es) | 2023-11-09 |
| WO2022177428A1 (en) | 2022-08-25 |
| BR112023016682A2 (pt) | 2023-11-14 |
| EP4294387A1 (en) | 2023-12-27 |
| KR20230159380A (ko) | 2023-11-21 |
| US20240189311A1 (en) | 2024-06-13 |
| CA3210033A1 (en) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117042770A (zh) | 用于患有高脂血症或混合性血脂异常的他汀类不耐受患者的奥比塞曲匹与依折麦布的组合治疗 | |
| US6982157B1 (en) | Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methylsulfonyl)amino] pyrimidin-5-yl] (3r,5s) -3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3A4 | |
| MX2007015677A (es) | Formulacion de 1-[(3-hidroxi-adamant-1-ilamino)-acetil]-pirrolidin -2(s)-carbonitrilo de liberacion modificada. | |
| US20200113882A1 (en) | Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions | |
| JP2006520810A (ja) | Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートの経口吸収性を増加させる方法 | |
| KR101524165B1 (ko) | Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법 | |
| EP1272219B1 (en) | New combination of a betablocker and a cholesterol-lowering agent | |
| JP7524167B2 (ja) | Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 | |
| AU2014332200A1 (en) | HIV treatment formulation of atazanavir and cobicistat | |
| JP2025522785A (ja) | 多発性硬化症及び重症筋無力症に対する治療用チロシンキナーゼ阻害剤 | |
| JP2025516634A (ja) | ミエリンオリゴデンドロサイト糖タンパク質抗体疾患（ｍｏｇａｄ）の治療における使用のためのブルトンチロシンキナーゼ阻害剤 | |
| WO2021142062A1 (en) | Fumarate ester dosage forms with enhanced gastrointestinal tolerability | |
| CZ20024181A3 (cs) | Farmaceutické prostředky obsahující betablokátor | |
| JP2025534632A (ja) | 多発性硬化症治療のためのチロシンキナーゼ阻害剤 | |
| TW202547505A (zh) | 包含ａｚｄ０７８０之醫藥組合物 | |
| SK11092001A3 (sk) | Kombinácia vzájomne nereagujúcich liečiv obsahujúca inhibítor hmg-coa reduktázy a inhibítor, induktor alebo substrát p450 izoenzýmu 3a4 | |
| HUE030936T2 (en) | Use of fenofibrate or a derivative thereof for treating diabetic retinopathy | |
| HK1051325B (en) | New combination of a betablocker and a cholesterol-lowering agent | |
| ZA200105838B (en) | Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-YL] (3R,5S) -3,5-dihydroxyhept-6-enoic acid and an inhibitor inducer or substrate of P450 isoenzyme 3A4. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |